Stay updated with breaking news from Centauri Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr Jennifer Schneider appointed CEO, Dr Helen Bright joins as VP of Research Development, and Professor David Roblin will Chair the Board of Directors Senior appointments support acceleration
- UK-based RQ Biotechnology Ltd (RQ Bio) launches with funding from licensing deal with AstraZeneca for RQ Bio's existing early stage monoclonal antibodies...
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2 - read this article along with other careers information, tips and advice on BioSpace
- UK-based RQ Biotechnology Ltd (RQ Bio) launches with funding from licensing deal with AstraZeneca for RQ Bio's existing early stage monoclonal antibodies (mAbs) against SARS-CoV-2 with payments
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio's existing early-stage monoclonal antibodies (mAbs) against SARS-CoV-2 and right to exclusively